FTC clears Novartis/Alcon with conditions
Monday, 16 August 2010
Ron Knox
Health-care company Novartis has agreed to sell off a cataracts drug to a third party to ease the US Federal Trade Commission’s concerns about its merger with eye care rival and Texas-based Alcon.
PREMIUM Subscription required to view this article
This content can only be accessed by PREMIUM GCR subscribers.
A premium subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current and archived print & online content.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top